Skip to main content
All lobbying filings

Cencora, Inc.

Cencora, Inc. filed a Q1 report for Cencora, Inc. on April 20, 2026.

Lobbying for Cencora, Inc.

As filed: CENCORA, INC. for CENCORA, INC.

All filings by Cencora, Inc. · Everything Cencora, Inc. has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$1,150,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Medicare/Medicaid

Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Extend payment increase under CMS FY 2026 Medicare's Part B physician fee schedule. Protecting Patient Access to Cancer and Complex Therapies Act 2025 (H.R.4299) Reimbursement policies impacting drug shortages Part B drug pricing changes Preventing and Mitigating Generic Drug Shortages CMS FY 2026 Medicares Part B Physician Fee Schedule: Proposed Changes to Bonafide Service Fees

Pharmacy

Preventing and Mitigating Generic Drug Shortages Ensuring Seniors Access to Critical Medications Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426)- Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA) Support for Fair Pharmacy Reimbursement

Health Issues

Essential Medicines Strategic Stockpile Department of Defense Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pharmaceutical supply chain resilience National Defense Authorization Act FY2026 (NDAA) Supply Chain Resiliency Most Favored Nation drug pricing proposals Direct to Consumer proposals CMS Medicare Part B Physician Fee Schedule Rule Break Up Big Medicine Act (S. 3822) CMS FY 2026 Medicares Part B Physician Fee Schedule: Proposed Changes to Bonafide Service Fees Role and value of community specialty physicians and MSOs

Taxation/Internal Revenue Code

Global Intangible Low-taxed Income (GILTI) Territorial Economic Recovery Act (H.R. 363) The Medical Manufacturing, Economic Development, and Sustainability (MMEDS) Act (H.R. 3042) Restore Economic Vitality and Investment in the Virgin Islands Act (REVIVE VI Act) (858)

Trade (domestic/foreign)

Tariff proposed policies

 Bills named in this filing 8
  • H.R. 3164
    Ensuring Community Access to Pharmacist Services Act
  • S. 2426
    Equitable Community Access to Pharmacist Services Act
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • H.R. 4132
    Prescription Information Modernization Act of 2025
  • S. 2027
    Prescription Information Modernization Act of 2025
  • S. 3822
    Break Up Big Medicine Act
  • H.R. 363
    Territorial Economic Recovery Act
  • H.R. 3042
    MMEDS Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem